Combined drug and application thereof in preparing drugs for treating high-level cerebroma with postoperative recurrence and no response to standard treatment
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A high-level, drug-based technology, applied in drug delivery, drug combination, medical preparations containing active ingredients, etc., can solve the problem of no chemotherapy program and achieve the effect of prolonging survival
Active Publication Date: 2019-04-05
SICHUAN JIUZHANG BIO TECH CO LTD
View PDF3 Cites 1 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
[0006] Currently, there is no effective chemotherapy regimen for high-grade brain tumors that relapse after surgery and fail standard treatment
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1
[0030] Example 1 Combination drugs of the present invention
[0031] 1Chlorogenic acid injection
[0032] Weigh 350g of chlorogenic acid aseptically, add 850g of mannitol, and dispense into injections after preparation.
[0033] 2 Temozolomide capsules
[0034] Weigh 100 g of temozolomide aseptically, and pack them into capsules aseptically.
[0035] 3 how to use
[0036] First orally use temozolomide, and then continue to use chlorogenic acid injection according to the mass ratio of 300 (chlorogenic acid): 150 (temozolomide).
Embodiment 2
[0037] Example 2 Combination drugs of the present invention
[0038] 1 Chlorogenic acid oral tablet
[0039] Weigh 350g of chlorogenic acid aseptically, add 850g of mannitol and 250g of microcrystalline cellulose, and make oral tablets after compression.
[0040] 2 Temozolomide capsules
[0041] Weigh 100 g of temozolomide aseptically, and pack them into capsules aseptically.
[0042] 3 how to use
[0043] First orally use temozolomide, and then continue to use chlorogenic acid tablets according to the mass ratio of 300 (chlorogenic acid): 150 (temozolomide).
Embodiment 3
[0044] Example 3 Combination drugs of the present invention
[0045] 1Chlorogenic acid injection
[0046] Weigh 100g of chlorogenic acid aseptically, add 650g of mannitol, and dispense into injections after preparation.
[0047] 2 Temozolomide capsules
[0048] Weigh 100 g of temozolomide aseptically, and pack them into capsules aseptically.
[0049] 3 how to use
[0050] According to the mass ratio of 100 (chlorogenic acid): 100 (temozolomide), both temozolomide capsules and chlorogenic acid injection were used.
[0051] 4 Animal model: Temozolomide resistance animal model
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
PUM
Login to view more
Abstract
The invention provides a combined drug for treating high-level cerebroma with postoperative recurrence and no response to standard treatment. The combined drug contains chlorogenic acid and temozolomide in same or different dosages and used for simultaneously or singly dosing, and a pharmacologically acceptable carrier. The invention also provides a drug compound containing chlorogenic acid and temozolomide. The invention also provides an application of the combined drug and the drug compound in preparing the drugs for treating high-level cerebroma with postoperative recurrence and no responseto standard treatment. The drug compound or combined drug provided by the invention can be used for effectively treating high-level cerebroma with postoperative recurrence and no response to standardtreatment, is capable of effectively controlling, reducing and eliminating focus of high-level cerebroma with postoperative recurrence and no response to standard treatment, and is capable of obviously prolonging lifetime of patients suffering from high-level cerebroma with postoperative recurrence and no response to standard treatment.
Description
Technical field [0001] The invention specifically relates to the use of a combined medicine and a pharmaceutical composition in the preparation of a medicine for treating high-grade brain tumors that are ineffective in standard treatment for postoperative recurrence. Background technique [0002] Brain tumors, also known as intracranial tumors and brain tumors, refer to neurological tumors that occur in the cranial cavity, including tumors originating from neuroepithelium, peripheral nerves, meninges and germ cells, tumors of lymphoid and hematopoietic tissues, and tumors of the sella Craniopharyngioma and granular cell tumor. According to the "World Health Organization Central Nervous System (CNS) Tumor Classification (2016)", which integrates tissue phenotype and gene phenotype CNS tumor classification principles, brain tumors include diffuse astrocytes and oligodendrocyte tumors, Other astrocytic tumors, ependymal tumors, choroid plexus tumors, neurons and mixed neuron-glial ...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to view more 
Login to view more